MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases.
Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) facility that houses sequencing platforms such as Illumina’s NovaSeq, HiSeq X, HiSeq 2500, and the MiSeq. We also have 10X Chromium for Single Cell assays along with Miltenyi gentleMACS tissue dissociation platform. To support our high-throughput lab operations, we have installed the Promega Maxwell(R) RSC 48 System for extraction of automation. Our services offerings extends to Spatial Transcriptomics, Antibody Discovery services using Single Cell, CAR-T, CRISPR and Epigenetics. All of these solutions require extensive support on custom and advanced bioinformatics, a capability that we have developed in-house.
In addition to our wet-lab capabilities, we have built proprietary solutions to enable pharma and biotech companies accelerate their early drug discovery pipeline as well as aid in biomarker discovery for their companion diagnostics programs. Our proprietary cancer immunotherapy solution, OncoPept combines tumor-derived genomic and transcriptomic data to map the molecular features of the tumor and predict personalized cancer immunotherapy combinations with neoantigen vaccines for therapy. MedGenome was awarded the MedTech Breakthrough award for Biomedical research in 2018.
We also support human genetics research by leveraging our extensive infrastructure to access samples and data from patient records through collaborations with over 500 hospitals in India, combined with capabilities to perform population level genomic sequencing of individuals. Through our extensive presence in the Indian sub-continent, we have access to data that provides insights into genetic diversity of Indian population for more than 4,500 population groups. Bioinformatics pipelines built to analyse data from large-scale sequencing efforts will facilitate identifying novel human genetic knockouts and medically relevant variants for drug discovery research.
MedGenome is also founding member of the GenomeAsia 100K, an initiative to sequence 100,000 Genomes in Asia, which will enable us to provide a unique resource of genetic research for the world.
MedGenome Inc. is registered and headquartered in the State of Delaware having its address at 108 West 13th Street City of Wilmington County of New Castle Delaware 19801.
Dr. Stephan C Schuster is currently the Research Director and Professor at the Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technical University, Singapore. Dr .Schuster has over 15 years of experience setting up and operating centralized sequencing core labs at Max Plank Institute in Germany and Penn State in the US. He won the Science magazine’s break through of the year award in 2006 (runner up) and 2008 (Top 10). He was also awarded the Time Magazine’s top ten Scientific discoveries in 2008 and along with W. Miller was among Time magazine’s top 100 most influential people of 2009. His research interests include Metagenomics, Evolutionary Biology and ancient DNA.
Dr. I. C. Verma is currently the head of the Department of Genetic Medicine at Sri Ganga Ram Hospital, New Delhi. Previously he was a Professor of Pediatrics and Genetics in AIIMS, New Delhi. He received genetics training in the UK, USA & Switzerland. He is a Fellow of the Royal College of Physicians, London, the American Academy of Pediatrics, and the National Academy of Medical Sciences, New Delhi. He has received a number of national awards – Ranbaxy Science Award, ICMR, NAMS and BC Roy Medical Council award. He is a Member and Vice-chairman of the Ethics Committee of the International Human Genome Organization (HUGO) and serves as a genetics adviser for the WHO in Geneva, and to Roche Genetics in Basel. He has vast experience in genetic counseling, serving about 2000 cases with genetic problems every year, and bringing the benefits of genetics and genomics to large number of patients.
Dr. C. N. Ramchand serves as the Chief Executive Officer and President of Saksin Lifesciences Pvt Ltd. and MagGenome Technologies Pvt Ltd. Dr.Ramchand has 30 years of industrial and academic experience in the field of drug discovery, nanotechnology and nutraceuticals. He has held key leadership positions such as India Director at Kemin Industries, India and Vice President & Head of New Drug Discovery (biological) Research Programme at Sun Pharma Advances Research Centre (SPARC) India. He has also held the position of Joint Co-ordinator and Head, Laboratory Research Program at Biomedical Sciences, University of Sheffield and Northern General Hospital Sheffield, UK, a prestigious University Position. Prior to this he was the Sr. Scientist and Project Head at the Institute of Biological Psychiatry at University of Wales, Bangor, UK. Dr. Ramchand has published over 70 peer-reviewed papers in international journals, edited 5 books, has over 40 patents.
MedGenome Institutional Ethics Committee (MG-IEC) is an independent body constituted under the authority of the chairman with the primary goal of safeguarding the rights and wellbeing of research participants. The chairperson of MG-IEC is appointed from a different institution and the appointment of IEC members is solely based on their competence, experience and integrity.
The MG-IEC will review all types of research proposals involving human participants with a view to safeguard the dignity, rights, safety and wellbeing of all actual and potential research participants before approving the research proposals. The goals of research, however important, should never be permitted to override the health and wellbeing of the research subjects.
The MG-IEC will ascertain whether all the cardinal principles of research ethics viz., Autonomy, Beneficence, Non-maleficence, Respect for Free and Informed Consent, Respect for Human Dignity, Respect for Vulnerable Persons, Respect for Privacy and Confidentiality and Justice are taken care of in planning, conducting and reporting of the proposed research. For this purpose, it will look into the aspects of protocol review, selection of participants, voluntary participation of potential participants, informed consent process, risk benefit ratio, distribution of burden and benefit, maintenance of privacy and confidentiality and provisions for appropriate compensations. It will review the proposals before the commencement of the study as well as review periodically until the completion of the study through appropriate well-documented procedures.
|MEMBERS OF MG-IEC|
|Chairperson||Dr. Vijayalakshmi M|
|Member Secretary||Padmavathy R|
|Scientist||Dr. Lakshmi Mahadevan|
|Basic Medical Scientist||Dr. Kumaramanickavel G|
|Scientist||Dr. Ramchand CN|
|Legal Expert/Lawyer||Srijith PR|
|Philosopher||Dr. Rajamohan EK|
|Basic Medical Scientist||Dr. Álex Baby Paul|
|Lay Person||Babu AG|
|Social Scientist / Social Worker||Vinita Vijayakumar|
Phone Number : 9496665432 / 9940678632